Is Buying Anaptysbio Inc (NASDAQ:ANAB), Having Lower Short Interest a Winning Strategy?

September 15, 2018 - By Jack Shaw

The stock of Anaptysbio Inc (NASDAQ:ANAB) registered a decrease of 13.05% in short interest. ANAB’s total short interest was 2.32 million shares in September as published by FINRA. Its down 13.05% from 2.67 million shares, reported previously. With 292,600 shares average volume, it will take short sellers 8 days to cover their ANAB’s short positions. The short interest to Anaptysbio Inc’s float is 14.9%.

The stock increased 0.57% or $0.49 during the last trading session, reaching $86.11. About 437,712 shares traded or 29.89% up from the average. AnaptysBio, Inc. (NASDAQ:ANAB) has risen 165.85% since September 15, 2017 and is uptrending. It has outperformed by 150.23% the S&P500.

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company has market cap of $2.07 billion. The companyÂ’s proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases. It currently has negative earnings. It also has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Inc. to develop and commercialize an anti-PD-1 antagonist antibody and an anti-TIM-3 antagonist antibody (TSR-022), which are under clinical development; and an inflammation partnership with Celgene Corporation to develop an anti-PD-1 checkpoint agonist antibody (CC-90006) that is in clinical stage.

AnaptysBio, Inc. (NASDAQ:ANAB) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.